Media Articles Related to Lucentis (Ranibizumab)
Novartis announce licence change for leading sight loss treatment Lucentis® (ranibizumab)
Source: Eye Health / Blindness News From Medical News Today [2014.09.25]
Novartis has announced a change to the licence of Lucentis® (ranibizumab), which means treatment can now be offered without the need for monthly monitoring in patients with stable disease...
UK data presented at EURETINA 2014 showcase efficacy of EYLEA in clinical practice for the treatment of wet age-related macular degeneration
Source: Eye Health / Blindness News From Medical News Today [2014.10.05]
Bayer HealthCare reports that data have been presented at the 14th EURETINA congress in London, showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet...
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
Source: MedPageToday.com - medical news plus CME for physicians [2014.10.18]
(MedPage Today) -- This week's topics include fecal transplant capsules, stem cells for macular degeneration, exercise and depression in teens, and Ebola predictions.
Published Studies Related to Lucentis (Ranibizumab)
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]
OBJECTIVE: To explore the association between treatment for neovascular age-related macular degeneration (AMD) and incidence and timing of retinal pigment epithelium (RPE) tears in ranibizumab-treated patients versus control treatment. DESIGN: Results from 3 phase III clinical trials (ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in age-related macular degeneration [ANCHOR], Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related macular degeneration [MARINA], and A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization [CNV] with or without Classic CNV Secondary to Age-Related Macular Degeneration [PIER]) were retrospectively reviewed to identify patients who developed RPE tears during the study period, detected on fluorescein angiography performed at prespecified intervals. PARTICIPANTS: Patients with baseline and post-baseline angiographic assessments... CONCLUSIONS: As studied in these trials, no statistically significant differences in the incidence of RPE tears within a 2-year treatment period were observed in patients who received ranibizumab (0.5 or 0.3 mg) versus control treatment, although most RPE tears with ranibizumab occurred within 3 months of initiating treatment. Mean VA was better in patients who developed RPE tears while receiving ranibizumab than in those who received control treatment, suggesting a potential benefit of continued ranibizumab therapy in patients with neovascular AMD who developed RPE tears. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. [2011.10]
PURPOSE: Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO). DESIGN: Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial. PARTICIPANTS: We included 392 patients with macular edema after CRVO... CONCLUSIONS: On average, treatment with ranibizumab as needed during months 6 through 11 maintained the visual and anatomic benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after CRVO, with low rates of ocular and nonocular safety events. After sham injections for 6 months, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT in the sham/0.5 mg group to a level similar to that in the 2 ranibizumab treatment groups and an improvement in BCVA, but not to the same level as that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after CRVO. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]
PURPOSE:: To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone... CONCLUSION:: This pilot study is the first to prospectively identify a biologic signal that may indicate combination therapy with an easily administered well-tolerated eyedrop and ranibizumab is efficacious for the treatment of neovascular age-related macular degeneration. Further studies are warranted to validate this finding.
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. [2011.08]
PURPOSE: Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO). DESIGN: Prospective, randomized, sham injection-controlled, double-masked, multicenter trial. PARTICIPANTS: A total of 397 patients with macular edema after BRVO... CONCLUSIONS: At month 12, treatment with ranibizumab as needed during months 6-11 maintained, on average, the benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after BRVO, with low rates of ocular and nonocular safety events. In the sham/0.5 mg group, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT to a similar level as that in the 0.3 mg ranibizumab treatment group and an improvement in BCVA, but not to the extent of that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after BRVO. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. [2011.07]
CONCLUSION: In contrast to ranibizumab, current safety data for bevacizumab are incomplete and not yet robust. If the medical community remains committed to using intravitreal bevacizumab, it is critical to establish that it has an acceptable safety profile, supported by evidence-based medicine. Considerable further research is warranted to achieve this.
Clinical Trials Related to Lucentis (Ranibizumab)
Ranibizumab for the Inhibition of Neovascularization in Pterygia [Recruiting]
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration [Recruiting]
In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced
fluence PDT combination therapy with ranibizumab. The researchers hope to gain information
regarding the use of reduced fluence PDT combination therapy. The information gained from
this pilot study may prompt further definitive studies comparing the safety and efficacy of
both standard fluence PDT combination therapy, reduced fluence PDT combination therapy, and
The study will compare the use of combination therapy with ranibizumab and verteporfin PDT
to ranibizumab alone in patients with exudative age-related macular degeneration (AMD). All
patients will receive three consecutive monthly treatments with ranibizumab. Patients will
be randomized 1: 1:1 to 3 groups. Patients randomized to group 1 will receive only
ranibizumab. Patients randomized to group 2 will also receive one treatment with reduced
fluence (50% fluence) verteporfin PDT at day 0. Patients randomized to group 3 will also
receive one treatment with standard fluence verteporfin PDT. All patients will also be
evaluated for possible retreatment with ranibizumab and verteporfin PDT according to
established criteria. Thirty patients will be recruited from one U. S. sites. Randomization
will occur at the time of entry into the study. Follow-up will continue until month 12 (from
day 0) in all subjects.
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion [Recruiting]
This is a prospective, single-center, non-randomized clinical study on the impact of
intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning
and emotional well-being in subjects with central or branch retinal vein occlusion.
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus [Not yet recruiting]
The purpose of this study is to demonstrate that two investigational treatment regimens have
the potential to result in a superior visual acuity improvement as compared to a ranibizumab
pro re nata (PRN=as needed) treatment regimen.
Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma [Recruiting]
Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris
surface induced by an increased level of vascular endothelial growth factor (VEGF). In
progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits
aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is
often difficult to control and frequently results in loss of vision.
The aim of this study is to analyze the short- and long-term outcome after adjuvant
intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and
to analyze the role of ranibizumab within a holistic treatment regime.
Reports of Suspected Lucentis (Ranibizumab) Side Effects
Visual Acuity Reduced (192),
Cerebrovascular Accident (153),
Myocardial Infarction (119),
Drug Ineffective (101),
Visual Impairment (64),
Eye Haemorrhage (61),
Retinal Haemorrhage (61),
Malaise (60), more >>